{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Naing A"],"funding":["NCATS NIH HHS","NCI NIH HHS","Memorial Sloan Kettering Cancer Center","CytomX Therapeutics, Inc."],"pagination":["e002447"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8311335"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["9(7)"],"pubmed_abstract":["<h4>Background</h4>Probody<sup>®</sup> therapeutics are antibody prodrugs that are activated in the tumor microenvironment by tumor-associated proteases, thereby restricting the activity to the tumor microenvironment and minimizing 'off-tumor' toxicity. We report dose-escalation and single-agent expansion phase data from the first-in-human study of CX-072 (pacmilimab), a Probody checkpoint inhibitor directed against programmed death-ligand 1 (PD-L1).<h4>Methods</h4>In the dose-escalation phase of this multicenter, open-label study (NCT03013491), adults with advanced solid tumors (naive to programmed-death-1/PD-L1 or cytotoxic T-lymphocyte-associated antigen 4 inhibitors) were enrolled into one of seven dose-escalation cohorts, with pacmilimab administered intravenously every 14 days. The p"],"journal":["Journal for immunotherapy of cancer"],"pubmed_title":["CX-072 (pacmilimab), a Probody <b><sup>®</sup></b> PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study."],"pmcid":["PMC8311335"],"funding_grant_id":["P30 CA008748","UL1 TR003167","UL1 TR001863"],"pubmed_authors":["Autio KA","Gil-Martin M","Ott PA","Stroh M","Arkenau HT","Garcia-Corbacho J","Eskens FALM","Uboha N","Boni V","Hannah AL","Naing A","De Vries EGE","Bendell J","LoRusso P","Durm G","Spira A","Thistlethwaite F","Randhawa M"],"additional_accession":[]},"is_claimable":false,"name":"CX-072 (pacmilimab), a Probody <b><sup>®</sup></b> PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study.","description":"<h4>Background</h4>Probody<sup>®</sup> therapeutics are antibody prodrugs that are activated in the tumor microenvironment by tumor-associated proteases, thereby restricting the activity to the tumor microenvironment and minimizing 'off-tumor' toxicity. We report dose-escalation and single-agent expansion phase data from the first-in-human study of CX-072 (pacmilimab), a Probody checkpoint inhibitor directed against programmed death-ligand 1 (PD-L1).<h4>Methods</h4>In the dose-escalation phase of this multicenter, open-label study (NCT03013491), adults with advanced solid tumors (naive to programmed-death-1/PD-L1 or cytotoxic T-lymphocyte-associated antigen 4 inhibitors) were enrolled into one of seven dose-escalation cohorts, with pacmilimab administered intravenously every 14 days. The p","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Jul","modification":"2026-07-16T11:58:58.507Z","creation":"2022-02-11T07:39:10.406Z"},"accession":"S-EPMC8311335","cross_references":{"pubmed":["34301809"],"doi":["10.1136/jitc-2021-002447"]}}